Aaron Judge’s Healing Scan Shows Progress but Not Yet Game‑Ready, Targeting 2026 Return

Lede

A fresh MRI of New York Yankees slugger Aaron Judge indicates that his elbow is healing, yet the imaging shows the joint is still not robust enough for baseball activity. Despite the setback, Judge has publicly reiterated his goal to step back onto a field by the 2026 season.

Core Developments

Both SNY and MLB.com reported that the latest imaging, performed as part of Judge’s ongoing rehabilitation, demonstrates measurable improvement in the repaired ligament and surrounding tissue. The scans, taken after a series of physical‑therapy milestones, show that the graft is integrating and the inflammation has subsided. However, radiologists noted that the structural integrity of the elbow remains below the threshold required for the high‑velocity throws and bat swings demanded by professional baseball.

Judge, who missed the entire 2023 season following Tommy John surgery, has been on a carefully staged rehab protocol overseen by the Yankees’ medical staff. The recent imaging was the first full‑body assessment since his initial post‑surgery scan in early 2024. While the images confirm that the surgical repair is on track, the medical team concluded that the joint is “not yet ready for the stresses of baseball activities,” as phrased by the MLB.com report.

In response, Judge told reporters that he remains focused on the long‑term goal of returning to play, emphasizing that he does not view the imaging results as a failure but rather as a data point guiding the next phase of his rehab. He said his target remains the 2026 season, a timeline that aligns with the Yankees’ projected roster planning.

Why It Matters

Aaron Judge is more than a power hitter; he is the centerpiece of the Yankees’ offensive strategy and a major draw for fans worldwide. His 2022 MVP season, during which he shattered the franchise home‑run record, set expectations for a multi‑year stretch of elite production. The delay in his return reverberates through several layers of the organization.

From a competitive standpoint, the Yankees have had to reconfigure the top of their lineup, relying on younger players and trade acquisitions to fill the void left by Judge’s absence. While the team has remained in contention, the lack of a consistent 35‑plus home‑run threat alters game‑by‑game tactics, especially in late‑inning situations where a single swing can change the outcome.

Financially, Judge’s contract, signed in 2022, extends through the 2027 season and includes a $450 million guarantee. The Yankees’ payroll flexibility hinges on Judge’s health; a delayed return could affect decisions on free‑agent signings and extensions for other core players. Moreover, the franchise’s marketing and ticket‑sales projections have been built around Judge’s star power, with stadium attendance and merchandise sales reflecting his presence on the field.

On a broader scale, Judge’s rehabilitation timeline offers a case study for MLB teams handling high‑profile Tommy John recoveries. The league has seen an increase in pitchers undergoing the procedure, but position players—especially those reliant on power hitting—present a different set of biomechanical challenges. The Yankees’ cautious approach may influence how other clubs structure rehab programs for similar athletes.

Differing Viewpoints and Reactions

While both sources agree on the medical assessment, they highlight slightly different tones in the surrounding commentary. SNY emphasized Judge’s optimism, noting his statement that he “still expects to play in 2026” and that he “feels good about the progress.” The outlet framed the news as a hopeful sign for fans eager to see the “king of the long ball” back in the lineup.

In contrast, MLB.com focused more on the medical caution, quoting the team’s physicians as saying the current level of healing “does not yet meet the criteria for baseball activities.” The report suggested that the Yankees may need to extend the rehab timeline, potentially pushing back the 2026 target if subsequent scans show slower progress.

Analysts from both outlets offered perspectives on the implications. A Yankees beat writer for SNY speculated that if Judge returns in 2026, the team could align his comeback with an anticipated power surge from emerging prospects, creating a “dual‑threat” lineup. Meanwhile, MLB.com’s senior baseball analyst warned that lingering doubts about Judge’s elbow could affect his swing mechanics, possibly diminishing his power output even if he does return on schedule.

What’s Next

The Yankees’ medical staff has outlined the next steps: continued strength training, a gradual re‑introduction to weighted‑bat drills, and a follow‑up MRI slated for early 2025. Those scans will determine whether the elbow has reached the biomechanical thresholds required for live pitching and batting.

Should the next imaging confirm sufficient healing, Judge will likely begin a monitored on‑field program, starting with light tosses and progressing to full swing mechanics under the supervision of the team’s conditioning coaches. The organization has also indicated that any decision to activate Judge for regular‑season play will be made in consultation with him, his agents, and the league’s health‑policy committee.

If the 2025 scan still shows limitations, the Yankees may opt to push his return to the 2026‑27 window, adjusting roster construction accordingly. In that scenario, the club could explore short‑term trades for power hitters or rely on internal depth to sustain offensive production.

Beyond the Yankees, Judge’s progress will be watched closely by other teams contemplating the risk‑reward balance of signing or extending players recovering from major elbow surgery. His eventual return—whether in 2026 or later—will likely shape the narrative around the durability of power hitters in the modern, data‑driven era of baseball.